Finally, QLT Inc Makes a Move
Research - QLT Inc. (QLTI) finally made the move we had been waiting for – although it's perhaps not the move we had been hoping for.
PremiumAuthor Archives: Jake King
Titan Pharma’s Addiction Treatment is Headed to the FDA
Insights - Titan Pharmaceuticals’ (TTNP) implantable device for the treatment of opioid addiction performed as well as standard sublingual buprenorphine tablets in a phase 3 study, the … Continue Reading
Read now
Take a Moment to Appreciate this Chart
Insights - Lets take a quick look at the current state of affairs in biotech & biopharma. We write often about the IBB, which is iShares’ Nasdaq Biotechnology … Continue Reading
Read now
Bluebird’s Gene Therapy Wows in Sickle Cell Disease
Insights - Bluebird bio (BLUE) keeps hitting its marks. The first Sickle Cell patient treated with LengiGlobin, bluebird’s one-time gene therapy product, is producing healthy red blood cells, … Continue Reading
Read now
No Buyer, but Achillion Pharmaceuticals Finds a Partner
Insights - Achillion Pharmaceuticals (ACHN) announced after the close on Tuesday a worldwide license and collaboration arrangement with Janssen Pharmaceuticals, of Johnson & Johnson (JNJ), to develop … Continue Reading
Read now
You Might be Taking this Cholesterol Drug within a Few Years
Research - It’s been almost 30 years since the U.S. FDA approved the first statin to lower cholesterol, and the class remains the go-to therapy for treating hypercholesterolemia.
PremiumBluebird Clears up the Regulatory Path for LentiGlobin
Research - Following meetings with the U.S. FDA and Europe’s EMA, bluebird bio (BLUE) has clarity on the regulatory path for LentiGlobin BB305 in beta-thalassemia major. For … Continue Reading
Premium